← FDA DRUG APPROVALS

FDA ANDA · ANDA065011

CEFOXITIN

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA065011
TYPE
ANDA
ORIGINAL APPROVAL
2000-07-03
LATEST ACTION
2007-11-26
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

CEFOXITINDiscontinued
CEFOXITIN SODIUM EQ 10GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2007-11-26Labeling · Supplement 6AP
2004-02-13Labeling · Supplement 3AP
2001-07-23Manufacturing (CMC) · Supplement 2AP
2000-10-18Labeling · Supplement 1AP
2000-07-03OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →